# Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects

> **NCT00616655** · PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 456 (actual)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** eszopiclone
- **DRUG:** eszopiclone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00616655
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 456 (ACTUAL)
- **Last updated:** 2016-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00616655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00616655, "Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00616655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*